Maegim한국어

일양약품

007570KOSPISector: Pharma & Biotech
₩7,860 0.00%Market cap ₩150.0BAs of Jul 21, 2026 close · updated once daily
C
Grade C51.5 ptsTop 51% of 2,523 stocks
Financial strength
42.3
Growth momentum
30.5
Price attractiveness
77.1

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

42.3
How much debt does it carry relative to equity?
Debt-to-equity ratio
89.4%
✗ Below median · Top 72.6% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
86.3%
✗ Below median · Top 81.1% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
1.8%
✓ Above median · Top 42.2% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
2.9%
✓ Above median · Top 34.8% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

30.5
How much did revenue grow in a year?
Revenue growth (YoY)
1.3%
✗ Below median · Top 61.9% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
3.2%
✗ Below median · Top 56.9% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-54.9%
✗ Below median · Top 84.2% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-65.2%
✗ Below median · Top 75% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

77.1
Is the price expensive relative to earnings?
P/E (price-to-earnings)
21.7x
✓ Above median · Top 26.2% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.63x
✓ Above median · Top 19.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15